Literature DB >> 23085982

On-target and off-target-based toxicologic effects.

Daniel G Rudmann1.   

Abstract

Adverse toxicologic effects are categorized as chemical-based, on-target, or off-target effects. Chemical-based toxicity is defined as toxicity that is related to the physicochemical characteristics of a compound and its effects on cellular organelles, membranes, and/or metabolic pathways. On-target refers to exaggerated and adverse pharmacologic effects at the target of interest in the test system. Off-target refers to adverse effects as a result of modulation of other targets; these may be related biologically or totally unrelated to the target of interest. Both the risk assessment and development strategies used for xenobiotics are influenced by the understanding of the mechanism of toxicity. It is imperative that the toxicologic pathologist use the toxicologic and biologic data at hand and literature information on the target to form testable hypotheses related to whether a toxicity is chemical-based, on-target, or off-target. The objective of this session at the 2012 Society of Toxicologic Pathologists Symposium in Boston, Massachusetts, was to discuss chemical-based, on-target, and off-target-based effects and the scientific approaches used to aid in their human risk assessment.

Entities:  

Mesh:

Year:  2012        PMID: 23085982     DOI: 10.1177/0192623312464311

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  33 in total

1.  Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion.

Authors:  Esha T Shah; Akanksha Upadhyaya; Lisa K Philp; Tiffany Tang; Dubravka Skalamera; Jennifer Gunter; Colleen C Nelson; Elizabeth D Williams; Brett G Hollier
Journal:  Clin Exp Metastasis       Date:  2016-03-01       Impact factor: 5.150

2.  Machine learning on drug-specific data to predict small molecule teratogenicity.

Authors:  Anup P Challa; Andrew L Beam; Min Shen; Tyler Peryea; Robert R Lavieri; Ethan S Lippmann; David M Aronoff
Journal:  Reprod Toxicol       Date:  2020-05-16       Impact factor: 3.143

3.  Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies.

Authors:  Chao-Kai Chou; Yen-Liang Liu; Yuan-I Chen; Po-Jung Huang; Pei-Hsiang Tsou; Chun-Te Chen; Heng-Huan Lee; Ying-Nai Wang; Jennifer L Hsu; Jin-Fong Lee; Thomas E Yankeelov; Jun Kameoka; Hsin-Chih Yeh; Mien-Chie Hung
Journal:  ACS Sens       Date:  2020-02-19       Impact factor: 7.711

Review 4.  The biology and rationale of targeting nectin-4 in urothelial carcinoma.

Authors:  Elisabeth I Heath; Jonathan E Rosenberg
Journal:  Nat Rev Urol       Date:  2020-11-25       Impact factor: 14.432

5.  Characterization of acute biliary hyperplasia in Fisher 344 rats administered the indole-3-carbinol analog, NSC-743380.

Authors:  Sandy R Eldridge; Joseph Covey; Joel Morris; Bingliang Fang; Thomas L Horn; Karen E Elsass; John R Hamre; David L McCormick; Myrtle A Davis
Journal:  Toxicol Appl Pharmacol       Date:  2014-10-28       Impact factor: 4.219

6.  Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.

Authors:  Dylan J Martini; Sean T Evans; Yuan Liu; Julie M Shabto; Ogul E Uner; T Anders Olsen; Jacqueline T Brown; Greta Anne Russler; Lauren Yantorni; Sarah Caulfield; Jamie M Goldman; Bassel Nazha; Wayne B Harris; Viraj A Master; Omer Kucuk; Bradley C Carthon; Mehmet Asim Bilen
Journal:  Clin Genitourin Cancer       Date:  2021-11-12       Impact factor: 2.872

Review 7.  Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Authors:  Daniela Femia; Natalie Prinzi; Andrea Anichini; Roberta Mortarini; Federico Nichetti; Francesca Corti; Martina Torchio; Giorgia Peverelli; Filippo Pagani; Andrea Maurichi; Ilaria Mattavelli; Massimo Milione; Nice Bedini; Ambra Corti; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 8.  Genetically modified T cells for the treatment of malignant disease.

Authors:  Agnieszka Wieczorek; Lutz Uharek
Journal:  Transfus Med Hemother       Date:  2013-11-29       Impact factor: 3.747

Review 9.  Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.

Authors:  Joshua Seth Eaton; Paul E Miller; Mark J Mannis; Christopher J Murphy
Journal:  J Ocul Pharmacol Ther       Date:  2015-11-05       Impact factor: 2.671

10.  A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Authors:  Marieke F Fransen; Hreinn Benonisson; Wendy W van Maren; Heng Sheng Sow; Cor Breukel; Margot M Linssen; Jill W C Claassens; Conny Brouwers; Jos van der Kaa; Marcel Camps; Jan Willem Kleinovink; Kelly K Vonk; Sandra van Heiningen; Ngaisah Klar; Lianne van Beek; Vanessa van Harmelen; Lucia Daxinger; Kutty S Nandakumar; Rikard Holmdahl; Chris Coward; Qingshun Lin; Sachiko Hirose; Daniela Salvatori; Thorbald van Hall; Cees van Kooten; Piero Mastroeni; Ferry Ossendorp; J Sjef Verbeek
Journal:  J Immunol       Date:  2018-03-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.